Sanofi India Limited (IN:SANOFI)
:SANOFI
Want to see IN:SANOFI full AI Analyst Report?
SANOFI Stock Chart & Stats
₹4142.75
₹54.40(0.91%)
At close: 4:00 PM EST
₹4142.75
₹54.40(0.91%)
Day’s Range― - ―
52-Week Range₹3,151.05 - ₹6,399.95
Previous CloseN/A
Volume15.46K
Average Volume (3M)3.77K
Market Cap
₹79.01B
Enterprise Value₹76.45B
Total Cash (Recent Filing)₹3.13B
Total Debt (Recent Filing)₹209.00M
Price to Earnings (P/E)38.1
Beta0.87
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.73%
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,030,000
10 Day Avg. Volume3,778
30 Day Avg. Volume3,766
Financial Highlights & Ratios
PEG Ratio6.96
Price to Book (P/B)12.56
Price to Sales (P/S)5.12
P/FCF Ratio22.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)165.03
Revenue Forecast (FY)₹19.50B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage provides durable financial flexibility, lowering solvency and refinancing risk and enabling sustained capital allocation to R&D, manufacturing, dividends or opportunistic M&A. Over a 2–6 month horizon this supports resilience to market shocks and operational stress.
Strong Free Cash FlowFree cash flow closely tracking net income and strong 2025 FCF growth indicate high earnings quality and genuine cash generation capacity. Durable FCF supports reinvestment, dividend payments and working-capital needs, improving strategic optionality over months ahead.
High Operating ProfitabilitySustained double-digit operating and healthy net margins reflect structural cost efficiency and pricing power in core therapy areas. These margins underpin long-term cash generation and ROE, supporting competitiveness and the ability to fund product maintenance and commercial efforts.
Bears Say
Revenue WeaknessA weakening top line reduces scale benefits and raises the risk that fixed costs and commercial investments will outpace demand. Persistent or recurring revenue declines can erode market position and limit sustainable growth and reinvestment capacity over the medium term.
Gross Margin CompressionA large decline in gross margin materially impairs underlying earnings power and cash conversion. If driven by pricing pressure, input costs, or adverse mix, the compression is structural and will constrain free cash flow and profitability unless product mix or cost base is restored.
Volatile Operating Cash FlowVolatility in operating cash flow suggests working-capital swings or inconsistent cash conversion. Even with strong 2025 FCF, irregular OCF increases short-term liquidity and planning risk, complicating predictable funding for operations and strategic initiatives over coming months.
Sanofi India Limited News
SANOFI FAQ
What was Sanofi India Limited’s price range in the past 12 months?
Sanofi India Limited lowest stock price was ₹3151.05 and its highest was ₹6399.95 in the past 12 months.
What is Sanofi India Limited’s market cap?
Sanofi India Limited’s market cap is ₹79.01B.
When is Sanofi India Limited’s upcoming earnings report date?
Sanofi India Limited’s upcoming earnings report date is Apr 28, 2026 which is today.
How were Sanofi India Limited’s earnings last quarter?
Currently, no data Available
Is Sanofi India Limited overvalued?
According to Wall Street analysts Sanofi India Limited’s price is currently Overvalued.
Does Sanofi India Limited pay dividends?
Sanofi India Limited pays a Semiannually dividend of ₹75 which represents an annual dividend yield of 4.73%. See more information on Sanofi India Limited dividends here
What is Sanofi India Limited’s EPS estimate?
Sanofi India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sanofi India Limited have?
Sanofi India Limited has 23,030,000 shares outstanding.
What happened to Sanofi India Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sanofi India Limited?
Currently, no hedge funds are holding shares in IN:SANOFI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, epilepsy, allergy and vitamins, anti-histamines, and minerals and supplements under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. The company also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Technical Analysis
Abbott India Limited
―
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―